膽管癌 ：新型療法、未滿足的需求和目標產品展望報告，2026 年

市場概覽

• 預計到 2035 年，德國膽管癌市場規模將從約 2 億美元成長到 6.8 億美元。
• 推動市場成長的因素如下：
• 擴大標標靶治療和免疫療法的應用
• 擴大基於生物標記的治療策略的應用
• 市場規模的擴大是由高品質的癌症治療以及適用患者群體的擴大所推動的。
• 未來的成長將取決於精準腫瘤學和下一代標靶治療的進步。

膽管癌（膽道癌）的新治療方法及TPP見解

Thelansis 的「膽癌（膽道癌）：新型療法、未滿足的需求和 TPP 洞察報告，2026」對該適應症的關鍵新興治療方法和主要藥物發現機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、試驗設計和關鍵意見領袖 (KOL) 的見解。

膽管癌（膽道癌）概述

膽管癌（膽管癌）是一種起源於膽管上皮細胞的惡性腫瘤，由慢性膽管炎、FGFR2融合基因、IDH1/2突變以及KRAS突變等促進致癌性轉化的基因所引起。膽管癌可分為肝內型、門週型及遠端型。臨床表現為進行進行性阻塞性黃疸、搔癢、體重減輕和腹痛，其中門週型腫瘤可導致早期膽管阻塞。診斷需綜合運用MRI/MRCP、CA19-9、組織切片檢查和分子譜分析。腫瘤的可切除性取決於血管侵犯和轉移的程度。手術切除是唯一的根治性治療方法，Gemcitabine/順Cisplatin聯合度Durvalumab單抗是標準的第一線全身治療方案。對於適合分子分子標靶治療的患者，FGFR2和IDH1抑制劑是分子分子標靶治療的選擇之一。膽道引流可最佳化症狀控制。鑑於整體預後不良，早期整合安寧療護並制定治療目標至關重要。

主要亮點

• 根據預測，德國膽管癌確診病例將從 2025 年的約 4,388 例增加到 2035 年的 4,612 例。
• 膽管癌（CCA）是一種高度侵襲性的膽管惡性腫瘤，預後不良，存活期有限。
• 確診時疾病已發展到晚期，這仍然是疾病負擔和死亡率的重要因素。
• 分子譜分析正日益成為標靶治療方法的基礎。
• 隨著 FGFR 抑制劑、IDH 抑制劑和免疫療法的應用，治療選擇正在不斷增加。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更深入的見解，從而進一步豐富了研究成果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興治療方法的患者
• 大公司
• 主要作用機制
• 發布日期等的預測
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要治療方法的有效性
• 未滿足需求的關鍵領域
• 估算主要未滿足需求的市場規模
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵KOL洞察對領先新興治療方法的見解
• 意識
• 預期用途/處理線
• 對主要未滿足需求的滿意度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Genfit
• RedHill Biopharma Limited
• Eisai Co., Ltd.
• Incyte Corporation
• Servier
• Virogin Biotech Ltd.
• 3D Medicines（Beijing）Co., Ltd.
• TransThera Sciences（Nanjing）, Inc.
• Taiho Oncology, Inc.
• Boehringer Ingelheim
• Verismo Therapeutics
• Hutchmed
• Medivir
• Eli Lilly and Company
• Bold Therapeutics, Inc.
• Elevar Therapeutics
• Rigel Pharmaceuticals
• Compass Therapeutics
• Toray Industries, Inc.
• MacroGenics
• Cogent Biosciences, Inc.
• Pheast Therapeutics
• Leap Therapeutics, Inc.
• Seagen, a wholly owned subsidiary of Pfizer
• SOFIE
• TCR2 Therapeutics
• Alentis Therapeutics AG
• Elicio Therapeutics
• Arbele Pty Ltd.
• Apollo Therapeutics Ltd.
• Context Therapeutics Inc.
• Merck Sharp &Dohme LLC
• Celldex Therapeutics
• Hoffmann-La Roche

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 診斷和治療過程/演算法
• 領先的新興治療方法—概述和KOL洞察

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：一級市場調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興治療方法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興治療方法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Cholangiocarcinoma (Bile Duct Cancer) Emerging Therapy and TPP Insights

Thelansis's "Cholangiocarcinoma (Bile Duct Cancer) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Cholangiocarcinoma (Bile Duct Cancer) Overview

Cholangiocarcinoma is a malignancy arising from biliary epithelial cells, classified as intrahepatic, perihilar, or distal, driven by chronic biliary inflammation, FGFR2 fusions, IDH1/2 mutations, and KRAS alterations promoting oncogenic transformation. It presents with progressive obstructive jaundice, pruritus, weight loss, and abdominal pain, with perihilar tumors causing early biliary obstruction. Diagnosis integrates MRI/MRCP, CA19-9, and tissue biopsy with molecular profiling; vascular involvement and metastatic spread define resectability. Surgical resection remains the only curative option; gemcitabine-cisplatin with durvalumab is the standard first-line systemic regimen. FGFR2 and IDH1 inhibitors provide targeted options in molecularly selected patients. Biliary drainage optimizes symptom control. Early palliative integration and goals-of-care planning are essential given poor overall prognosis.

Key Highlights

• In Germany, diagnosed cholangiocarcinoma cases are projected to increase from approximately 4,388 in 2025 to 4,612 by 2035.
• CCA remains an aggressive biliary tract malignancy associated with poor prognosis and limited survival.
• Late-stage diagnosis continues to contribute to significant disease burden and mortality.
• Molecular profiling is increasingly enabling targeted treatment approaches.
• FGFR inhibitors, IDH inhibitors, and immunotherapies are expanding therapeutic options.

Market Overview

• The Germany cholangiocarcinoma market is projected to grow from approximately $200 MN to $680 MN by 2035.
• Market growth is supported by:
• Increasing adoption of targeted therapies and immunotherapy
• Growing use of biomarker-driven treatment strategies
• Market value growth is driven by premium oncology therapies and expanding eligible patient populations.
• Future growth will depend on precision oncology advancements and next-generation targeted treatments.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Genfit
• RedHill Biopharma Limited
• Eisai Co., Ltd.
• Incyte Corporation
• Servier
• Virogin Biotech Ltd.
• 3D Medicines (Beijing) Co., Ltd.
• TransThera Sciences (Nanjing), Inc.
• Taiho Oncology, Inc.
• Boehringer Ingelheim
• Verismo Therapeutics
• Hutchmed
• Medivir
• Eli Lilly and Company
• Bold Therapeutics, Inc.
• Elevar Therapeutics
• Rigel Pharmaceuticals
• Compass Therapeutics
• Toray Industries, Inc.
• MacroGenics
• Cogent Biosciences, Inc.
• Pheast Therapeutics
• Leap Therapeutics, Inc.
• Seagen, a wholly owned subsidiary of Pfizer
• SOFIE
• TCR2 Therapeutics
• Alentis Therapeutics AG
• Elicio Therapeutics
• Arbele Pty Ltd.
• Apollo Therapeutics Ltd.
• Context Therapeutics Inc.
• Merck Sharp & Dohme LLC
• Celldex Therapeutics
• Hoffmann-La Roche

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)